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A Ab bs st tr ra ac ct t
Multiple colonic polyps, almost guaranteed colorectal cancer by the age of forty-five and an increased risk of
non-colonic cancers characterise the autosomal dominant condition Familial Adenomatous Polyposis (FAP) [1].
The patients and families faced with such a diagnosis present many difficult management challenges, both
surgical and non-surgical. We discuss the current surgical options for treatment of the more significant
manifestations of FAP arising in the colorectum and duodenum as well as desmoid disease
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C Co ol lo or re ec ct ta al l   d di is se ea as se e
Of the many adenomatous polyps which develop
in the colon and rectum of patients with FAP , “...one
or more of the adenomata form... a malignant
adenocarcinoma” [2]. Cancer preventative surgery
was instituted in the 1940’s. Subsequently screening
of  patients  with  a  family  history  of  FAP  was
commenced to ensure that prophylactic treatment,
including surgery, was being offered [3]. The timing
of prophylactic surgery depends on various factors,
such as age. Although there are reports of carcinoma
of the rectum developing in children aged less than
10 years [4], elective surgery is usually deferred until
after puberty. Quality of life issues for an adolescent
are  very  different  from  that  of  an  adult,  often
influenced by schooling, and this is factored into the
planning of surgery. Most patients should have been
offered a colectomy by the start of their third decade
of life, as 15% of FAP patients will present with
colorectal  cancer  before  the  age  of  25  [5];
surveillance usually starts from the age of 10 [6].
The nature of the prophylactic surgery performed
depends on the clinical findings pre-operatively, the
patients’ wishes and the surgeons’ preference (Table
1, Fig. 1) [7].
P Pr ro oc ce ed du ur re e
T To ot ta al l   c co ol le ec ct to om my y   a an nd d   i il le eo or re ec ct ta al l   a an na as st to om mo os si is s   ( (I IR RA A) ). .
This procedure is unsuitable in patients with marked
rectal polyposis and/or rectal carcinoma, or when
adequate follow-up and surveillance of the rectal
stump cannot be guaranteed [8-10]. The procedure
entails mobilisation of the whole colon to the point
at which the taeniae coli fuse, considered the upper
border  of  the  rectum.  Dissection  to  this  level
maintains the reservoir function of the rectum and
ensures that the anastomosis can be reached with
ease by the rigid sigmoidoscope for surveillanceH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 154
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purposes. A simple ileorectal anastomosis is fashioned
either hand-sewn or stapled. To eliminate blind loops,
inaccessible to rigid sigmoidoscopy, formation of an
end-to-end anastomosis is recommended [11, 12].
P Pr ro oc ct to oc co ol le ec ct to om my y. This is either total or restorative.
The former involves a permanent ileostomy and will
not be discussed in detail. The latter, first described
in  1978  [13],  avoids  a  permanent  stoma  by
constructing a new reservoir which is re-anastomosed
to the anal canal. This panproctocolectomy with ileal
pouch-anal anastomosis (IPAA) requires the whole
colon and rectum to be mobilised and the large
bowel  removed  by  dividing  the  intestine  at  the
ileocaecal and anorectal junctions. The reservoir is
fashioned from the terminal ileum and this in turn is
anastomosed to the anal canal.
I In nd di ic ca at ti io on ns s. .   The phenotype of the individual FAP
patient and any symptoms experienced at presentation
are the most important factors determining which
surgical procedure is carried out [6, 8, 9, 12]. 
T Ta ab bl le e   1 1. .   Indications and advantages of colectomy options in patients with FAP
T To ot ta al l   c co ol le ec ct to om my y   + +   i il le eo or re ec ct ta al l   a an na as st to om mo os si is s R Re es st to or ra at ti iv ve e   p pa an np pr ro oc ct to oc co ol le ec ct to om my y
I In nd di ic ca at ti io on ns s • Rectal sparing • Rectal cancer
• Sparse polyposis • Multiple rectal polyps
• Compliant with follow-up • Widespread colorectal polyps
• Non-compliant with follow-up
A Ad dv va an nt ta ag ge es s • Less operative morbidity • ⇓ Rectal cancer risk
• Larger reservoir function • Less frequent surveillance
D Di is sa ad dv va an nt ta ag ge es s • ⇑ Rectal cancer risk • Longer procedure
• Rectal surveillance every 6 months • Greater complication rate
• IPAA or ileostomy may be required at a later date • Likely two-stage procedure
• Poorer functional outcome
F Fi ig g. .   1 1. .   Decision tree for colorectal surgical options in FAP
F FA AP P   C Co on nf fi ir rm me ed d
R Re ec ct ta al l   C Ca an nc ce er r
S Sp ph hi in nc ct te er rs s   i in nv vo ol lv ve ed d/ /c co om mp pr ro om mi is se ed d
R Re ec ct ta al l   P Po ol ly yp ps s
L Li ik ke el ly y   t to o   c co om mp pl ly y   w wi it th h   s su ur rv ve ei il ll la an nc ce e
P Pr ro oc ct to oc co ol le ec ct to om my y   + +   E En nd d
I Il le eo os st to om my y
R Re es st to or ra at ti iv ve e   P Pr ro oc ct to oc co ol le ec ct to om my y   w wi it th h   p po ou uc ch h
f fo or rm ma at ti io on n
T To ot ta al l   C Co ol le ec ct to om my y   + +   I Il le eo or re ec ct ta al l
a an na as st to om mo os si is s
Y Ye es s
Y Ye es s
M Mu ul lt ti ip pl le e N No on ne e/ /F Fe ew w
N No ot t
C Co om mp pl li ia an nt t C Co om mp pl li ia an nt t
N No o
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O Op pe er ra at ti iv ve e   m mo or rb bi id di it ty y   a an nd d   m mo or rt ta al li it ty y. . Total colectomy
and IRA are considered a relatively safe procedure with
a low operative mortality [9]. There is a fairly steep
learning curve with IPAA but the operative mortality can
be as good as IRA [14]. IPAA is more likely to be a two-
stage procedure with a temporary defunctioning ileostomy
requiring subsequent closure often being formed, but
such stomas are not always necessary [8, 15].
F Fu un nc ct ti io on na al l    o ou ut tc co om me e. . Whilst  increased  bowel
frequency [8, 16] and urgency [16] are common
following IRA, patients experience nocturnal defecation
[8, 17], greater use of anti-diarrhoeal medication [18],
and problems with faecal soiling, incontinence and
flatus/faeces  discrimination  [17,  19]  are  more
commonly  following  IPAA  procedures.  Studies
comparing IRA and IPAA procedures have shown
similar overall quality of life outcomes [20].
The preservation of the pelvic sympathetic plexus is
considered a relative indication for IRA in young men [21]. 
P Po os st t- -o op pe er ra at ti iv ve e   s su ur rv ve ei il ll la an nc ce e
I Il le eo or re ec ct ta al l   a an na as st to om mo os si is s. . Having an IRA implies lifelong
surveillance with a minimum of rigid sigmoidoscopy every
6 months [6], although sigmoidoscopy every 4 months
has been suggested [5]. Standard polyp surveillance
should be carried out with all remaining polyps removed
[22]. A combination of snare polypectomy or diathermy
is appropriate. The risk of rectal cancer increases with
chronological age rather than time from surgery [5, 11,
12] with an approximately 25% risk of rectal cancer by
the age of 70 years [11]. The cumulative risk for rectal
excision following IRA may be as high as 60% for those
aged 70 years [11].
Bjork et al found many of the rectal cancers had
developed very close to the anal verge, a notoriously
difficult area to assess with the rigid sigmoidoscope
[11]. In a like manner, patients in whom an IRA has
been constructed higher than 12 cm from the anal
verge are more likely to develop rectal cancer as the
rectum  cannot  be  adequately  assessed  in  rigid
sigmoidoscopy [11, 12]. Older age at the time of IRA
and multiple/dense pre-operative polyps are additional
risk factors for the development of rectal cancer;
however, these factors would preclude a patient from
receiving an IRA today. Church et al investigated this,
finding that in the past all patients were offered 
a  sphincter  sparing  procedure  (IRA)  before  IPAA
became widely available. They found that all patients
with very severe polyposis had an IRA in the pre-pouch
era and only 39% with severe polyposis had chosen
this in the pouch era [23]. They hypothesised and showed,
albeit with a shorter period of follow-up, that patients who
have an IRA in the pouch-era have a lower risk of post
IRA rectal cancer than those operated during the pre-
pouch era. Attributing this to patient selection (that is,
those with less severe phenotypes now receive an IRA)
they cautioned that the choice of surgery now should not
be influenced by data that were generated before the
current range of surgical options became available.
I Il le ea al l   p po ou uc ch h- -a an na al l   a an na as st to om mo os si is s. . With increasing
reports of adenomas [24, 25] and even carcinomas
[26] in pouches, regular surveillance of these is
advocated, with most groups suggesting annual rigid
sigmoidoscopy [6] (Fig. 2). 
C Co on nt tr ro ov ve er rs si ie es s   i in n   I IP PA AA A. . As FAP is primarily a mucosal
disease it seems logical to remove all the colorectal
mucosa  to  prevent  polyps  and  ultimately  cancer
developing at a later date. Mucosectomy was an
essential part of Parks and Nicholls’ original description
[13]. To avoid this time-consuming component of
restorative proctocolectomy double stapled anastomoses
are used [19, 27-29]. Stapled anastomoses leave 
a greater cuff of mucosa than that left following
mucosectomy and hand-sewn anastomosis [30], with
pouch/anal polyps seen more commonly following
stapled than with hand-sewn IPAA [30].  
Patients subjected to a hand-sewn anastomosis are
more likely to experience a poorer functional outcome
[14, 29], with increased bowel action and faecal
incontinence  more  common  [29].  This  may  be 
a consequence of the anal stretch required to facilitate
the anastomosis, or the removal of the anal transitional
zone  during  the  mucosectomy  [26].  The  anal
transitional zone, a highly innervated area 1 cm above
the dentate line, is believed to be responsible for the
discrimination of faeces and flatus [26, 31]. Pouch-anal
strictures do occur, with reported rates as high as 42%
[27, 29]. They are more commonly found following
stapled anastomoses [27]. Strictures following stapled
anastomoses tend to be less troublesome and more
amenable to simple dilatation than those which occur
in hand-sewn anastomosis; which are inclined to be
more severe, requiring operative dilatation [27].
Pouchitis, often seen in IPAA procedures carried out
for inflammatory bowel disease [32], is very unusual
in FAP patients [17, 29].
D Du uo od de en na al l   p po ol ly yp po os si is s
Extra-colonic polyps have been described in the
stomach and duodenum of FAP patients for over 100years [1], but their true incidence and significance
were only fully documented in the late 1980’s [33,
34]. It is now recognised that up to 90% of FAP
patients will develop duodenal polyposis by the age
of 70 [35], and once colectomy has been carried
out duodenal cancer is one of the main causes of
death in FAP patients [36, 37]. As part of their
prospective study of duodenal polyposis in FAP
patients, Spigelman et al defined a now widely used
classification score for severity of duodenal polyposis
[33] (Table 2a). 
S Su ur rv ve ei il ll la an nc ce e. . The  first  surveillance  upper
gastrointestinal endoscopy should be carried out by
the age of 25-30 [36, 38, 39]. This should then be
followed up by a further endoscopy 12 months later
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F Fi ig g. .   2 2. . Decision tree for surveillance following colonic surgery in FAP
S Su ur rg ge er ry y
T To ot ta al l   C Co ol le ec ct to om my y   + +   I IR RA A
6 6   M Mo on nt th hl ly y 6 6   M Mo on nt th hl ly y
P Po ol ly yp p   A Ab bl la at ti io on n
P Po ol ly yp ps s   c co on nt tr ro ol ll le ed d
S Su ur rv ve ei il ll la an nc ce e   a as s   b be ef fo or re e P Pr re ev vi io ou us s   I IR RA A P Pr re ev vi io ou us s   I IP PA AA A
P Po ou uc ch h   e ex xc ci is si io on n   
+ +   E En nd d   i il le eo os st to om my y I IP PA AA A
Y Ye es s N No o
S St ta ap pl le ed d H Ha an nd d- -s se ew wn n
Y Ye ea ar rl ly y
R Re es st to or ra at ti iv ve e   p pr ro oc ct to oc co ol le ec ct to om my y   ( (I IP PA AA A) )
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[36], and a Spigelman stage derived. Random biopsies
of apparently normal mucosa should also be taken
initially, with Bulow et al finding 12% of adenomas in
their series to be invisible [35]. The region of the
ampulla is of considerable importance and this is best
viewed and biopsied with a side or oblique-viewing
endoscope [33]. A suitable surveillance program based
on the Spigelman stage is then employed [40] (Table
2b). Disease progression does occur and Spigelman
stage IV patients have a crude risk of developing
duodenal cancer of 36% [40], compared with 2% for
those with stage II or III disease.
E En nd do os sc co op pi ic c    t tr re ea at tm me en nt ts s. . Various  endoscopic
treatments have been used to control duodenal
adenomas locally. These include polyp ablation by
electro-diathermy, Nd-YAG laser, ionised argon
diathermy, photodynamic therapy, snare polypectomy
and mucosal resection [38, 39]. These procedures
have a risk of complications including bleeding,
perforation, and pancreatitis as well as late-onset
duodenal stenosis [39]. Recurrence is also likely [36,
41], making the decision to persevere with further
endoscopic  treatments  or  proceed  to  surgery 
a difficult one.
S Su ur rg ge er ry y. . If duodenal carcinoma has developed 
a pancreaticoduodenectomy (Whipple’s or modified
Whipple’s procedure) should be carried out [39]. For
patients  with  benign  adenomatous  change  but
Spigelman  stage  IV  less  radical  surgery  can  be
performed. Recent advances in surgical technique have
resulted in pancreas or pylorus sparing duodenectomy
being carried out [41-43]. Such procedures involve
resection of the whole of the duodenum with its
associated malignant potential, preserving the function
of  the  pylorus  and/or  the  pancreas.  This  is  of
considerable importance to patients who have already
had a colectomy, as daily bowel movements can be
doubled, particularly in patients with an IPAA [41].
C Ch he em mo op pr re ev ve en nt ti io on n. .   Trials of the non-steroidal anti-
inflammatory drugs (NSAIDs) Sulindac and Celecoxib
(COX-2 inhibitor) have shown regression of duodenal
polyps [44] and their use is probably best reserved for
patients with stage III or IV (initially) polyposis [38].
F Fu ut tu ur re e   d de ev ve el lo op pm me en nt ts s. . Jejunal and ileal polyps occur
in FAP patients [42]. The advent of capsule endoscopy
will allow for a more precise estimation of their
prevalence and natural history. Similar advances in CT
T Ta ab bl le e   2 2a a. .   Spigelman Staging [33] of Duodenal Polyposis
P Po oi in nt ts s   a as ss si ig gn ne ed d
C Ch ha ar ra ac ct te er ri is st ti ic c 1 1 2 2 3 3
No. of polyps 1 to 4 5 to 20 >20
Polyp size (mm) 1 to 4 5 to 10 >10
Histology tubular tubulovillous villous
Dysplasia mild moderate severe
Scoring system: Stage 0 = 0 points
Stage I = 1 to 4 points
Stage II = 5 to 6 points
Stage III = 7 to 8 points
Stage IV = 9 to 12 points
T Ta ab bl le e   2 2b b. .   Suggested surveillance/treatment fro Duodenal Polyposis based on Spigelman Staging [38]
S Sp pi ig ge el lm ma an n   s st ta ag ge e E En nd do os sc co op pi ic c   s su ur rv ve ei il ll la an nc ce e T Tr re ea at tm me en nt t
S St ta ag ge e   0 0 5 yearly -
S St ta ag ge e   I I 5 yearly -
S St ta ag ge e   I II I 3 yearly No surgery
Chemoprevention equivocal
S St ta ag ge e   I II II I 1-2 yearly Surgery equivocal
Chemoprevention offered
S St ta ag ge e   I IV V 6 monthly Surgery offered
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imaging herald hope for less invasive surveillance of
the duodenum [45].
D De es sm mo oi id d   d di is se ea as se e
Desmoid tumours account for 0.03% of all tumours
in the non-FAP population, but occur in up to 32% of
those with FAP [46]. They result from proliferation of
myofibroblasts [47], arising within the abdomen or the
abdominal  wall  in  FAP  patients.  They  are  more
common  in  women,  particularly  in  the  non-FAP
population, leading to the suggestion that female
hormones may play some role in their development
[48, 49]. There is a tendency for desmoids to run in
certain FAP families and previous trauma or surgery is
thought to initiate their development. The St. Mark’s
group have described early desmoid tumour type
lesions (desmoid precursor lesion) in people who have
no  history  of  surgery  or  trauma  [50]  but  their
significance has yet to be fully assessed.
Desmoid tumours are classified as benign as they
do not spread to distant sites; however they are
potentially lethal when they occur within the abdominal
cavity by surrounding other structures such as small or
large bowel, ureters and the mesentery [51].
S Su ur rg ge er ry y
D De es sm mo oi id d   t tu um mo ou ur rs s   o of f   t th he e   a ab bd do om mi in na al l   w wa al ll l   a an nd d   t th he e
e ex xt tr re em mi it ti ie es s. . It is recommended that surgery should
include excision of the mass with some surrounding
tissue.  This  can  be  done  with  relatively  few
complications but the recurrence rate varies from 10%
to 68% [46].
D De es sm mo oi id d   t tu um mo ou ur rs s   w wi it th hi in n   t th he e   a ab bd do om me en n. .   Surgery is
often  technically  demanding  and  may  even  be
impossible. The complication rate is high with a post-
operative mortality rate of anywhere between 10%
and 60%, and a recurrence rate of up to 78% [46].
It is recommended that desmoid tumours should only
be surgically removed when bowel obstruction has
occurred or when the blood supply to the bowel has
been compromised. As operative removal is complex
this should be done by experienced surgeons [7, 52].
A recent report found the presence of incidental
desmoid tumours at laparotomy for colectomy that
required modifications or precluded the intended
procedure from being carried out in 26% of 266
patients [47].
With  a  risk  of  recurrence  following  surgical
removal, various other treatment modalities have
been trialled.
O Ot th he er r    t tr re ea at tm me en nt t    m mo od da al li it ti ie es s. . Commonly  used
NSAIDs like Sulindac have been shown to cause some
reduction in the size or to halt further enlargement of
desmoid tumours [53, 54]. Anti-oestrogen drugs such
as Tamoxifen have been studied, in conjunction with
NSAIDs, providing similar results to the use of NSAIDs
alone [54-56]. Cytotoxic chemotherapy has been
found to be similarly effective as the NSAIDs and anti-
oestrogens but with more marked side effects. The use
of  chemotherapy  is  currently  reserved  for  large
inoperable desmoid tumours that have not responded
to other drug treatments [57-60]. Radiotherapy is not
recommended in FAP , as most tumours are within the
abdomen  and  unacceptable  post-treatment
complications affecting the small bowel may occur [7,
46]. Warfarin, Prednisolone and Interferon have been
used, but without evidence from clinical trials [46, 61].
S Su um mm ma ar ry y    o of f    t tr re ea at tm me en nt t    o op pt ti io on ns s. . For  desmoid
tumours of the abdominal wall and extremities wide
surgical excision is recommended. If recurrent, further
surgery may be attempted and radiotherapy may be
used for tumours of the extremities [51].
Intra-abdominal  desmoid  tumours  should  be
assessed every 6-12 months with CT scan and medical
management with NSAIDs (Sulindac) with Tamoxifen
may be beneficial. Renal tract obstruction may require
ureteric stent insertion [53]. If progression occurs the
dose of Sulindac can be increased and Tamoxifen
replaced  with  Toremifene  [46].  This  should  be
maintained for several years before dose reduction is
considered. If further progression of the desmoid
tumour occurs or they become more symptomatic
surgery  may  be  attempted  either  to  remove  the
desmoid tumours if a small discrete mass and no vital
structures are involved; or palliative surgery to relieve
the symptoms. When surgery is not possible or there
has  been  subsequent  recurrence  then  cytotoxic
chemotherapy may be considered [46].
P Pr ro og gn no os si is s. . About 4-6% of desmoid tumours resolve
spontaneously [46, 52]. Desmoid tumours cause
significant morbidity and in cases of unresectable
mesenteric desmoid tumours the mortality rate has
been reported to be as high as 30%. The overall
survival rate after 10 years is 63% [46].
S Su ur rv ve ei il ll la an nc ce e   a an nd d   c ca an nc ce er r   r re eg gi is st tr ri ie es s
The importance of familial cancer registries cannot
be  underestimated.  The  familial  cancer  registry
undertakes the time-consuming task of documenting
the full family pedigree, followed by the requisite
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genetic counselling [62]. They may also coordinate
genetic testing as appropriate, family member contact
and provide assistance to ensure that surveillance is
being performed. It is noteworthy that “all published
data from cancer prevention programmes that have
reduced cancer incidence in family members... have
used family [cancer] registries” [63].
C Co on nc cl lu us si io on n
Surgical management of FAP has improved over the
years with a greater emphasis on preventative/prophylactic
surgery.  Deciding  which  prophylactic  large  bowel
procedure is difficult. With such prophylactic procedures
almost eliminating the risk of colorectal cancer, patients
with  FAP  now  face  new  challenges  from  duodenal
polyposis and desmoid disease. 
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